P 1037

Drug Profile

P 1037

Alternative Names: GS-5737; P-1037; VX 371

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Parion Sciences
  • Developer Parion Sciences; Vertex Pharmaceuticals
  • Class Antibronchitics
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Primary ciliary dyskinesia

Most Recent Events

  • 25 Oct 2017 Safety and efficacy data from a phase IIa trial in Cystic fibrosis released by Vertex Pharmaceuticals
  • 01 Sep 2017 Vertex Pharmaceuticals completes a phase II trial in Cystic fibrosis (In adolescents, In adults) in USA, United Kingdom, Czech Republic, France and Ireland (Inhalation) (NCT02709109)
  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for P 1037 in USA and outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top